Poster Abstracts
H Mouton-Sclaunich, ; Rekik, ; Marchand, ; Bordage, ; Proux, ; Brousseau, ; Chenailler, ; Varin, ; Doucet, ; Dubois, ; Vanheste, ; Berthomier, ; Soubieux, ; Thomassin, ; Gleye, ; Rolland, ; Vittecoq, S Afach, ; Chaimani, ; Penso, ; Brouste, ; Sbidian, ; Le Cleach, C Bordet, V Rousseau, F Montastruc, J Montastruc, V Gras-Champel, ; Bertrand, ; Piedeloup, ; Liabeuf, U Houngue, ; Chaker, ; Remila, ; Brucker, ; Park, ; Belcastro, ; Bouchakour, ; Tokoudagba, ; Auger, ; Gbaguidi, Schini-Kerth, E Frauger, V Pauly, M Cepeda, L Rasmussen, E Frauger, P Tuppin, V Pradel, V Pradel, M Marius, Hoeper, Keiko, E Willems, M Correale, D Birgegard, P Burtin, T Caro-Patn, Lvy-Bruhl, J Souberbielle, S Benaboud, D Keywords ; Vitamin, K, M Yobo-Bi, ; Bni-Bi, ; Tour
Abstract
The risk of adverse drug event greatly increases with the number of illnesses and the number of drugs. The Admission Medication Reconciliation (AMR), managed by a multi-professional team, leads to more security for patient care. Medication reconciliation is daily organized in acute care medicine units (105 beds) of a university hospital. The aim of the study was to evaluate the clinical impact of AMR. Material and methods: We performed a retrospective study of Non-Intentional Discrepancies (NID) recorded in AMR from November 2018 to April 2019 (160 days). The AMR was obtained by the pharmaceutical team with a patient-risk-based prioritization by physicians. The Potential Clinical Impact (PCI) of the NID was separately evaluated by the physician and the clinical pharmacist using the CLEO clinical scale (4 severity grades). Results: 380 AMR were made in 28% of patients (average age 82 11 years). A total of 151 NID were recorded in 119 patients (0.4 NID per patient). After information to ordering physicians, 80 NID (53%) were corrected. 133 NID (88%) had the same grade of PCI according to the doctor and the pharmacist. Among the NID identically graduated by doctor and pharmacist, 29 (22%) had a PCI major to vital . The drugs concerned were notably 7 antiglaucoma drugs, 6 antiplatelet drugs, 4 anticoagulants, 1 anti-hormone (Ormandyl) and 1 oncologic drug (Hydrea). Discussion/Conclusion: NID were frequent and very often identically evaluated by the doctor and the pharmacist, with a frequent potential clinical impact major to vital . The concerned drugs were sometimes unusual. Therefore, the clinical interest of the AMR is confirmed and increases the security of medical prescription, notably when a pharmacist is present in the clinical unit. Further study will concern the prospective graduation of the PCI.